Form 4: Ionis Pharma Exec Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, sold 20,106 shares of common stock on March 3, 2026, under a pre-arranged 10b5-1 trading plan.
Summary
- Shannon L. Devers, EVP, Chief Human Resources Officer of Ionis Pharmaceuticals Inc. (IONS), reported transactions on March 3, 2026.
- Devers exercised non-qualified stock options to acquire a total of 20,106 shares of common stock at exercise prices ranging from $32.60 to $52.87 per share.
- Concurrently, Devers sold a total of 20,106 shares of common stock in multiple transactions at weighted average prices ranging from $79.115 to $80.837 per share.
- These sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted on November 24, 2025.
- Following these transactions, Devers directly beneficially owns 22,541 shares of Ionis Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While an executive selling shares could be seen negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about immediate insider sentiment, as these are typically for personal financial management.
Positives
- The executive exercised stock options, indicating a realization of value from previously granted equity compensation.
- Shares were sold at prices significantly higher than the exercise prices of the options, demonstrating a profitable transaction for the executive.
Negatives
- The executive sold a substantial number of shares (20,106), which could be interpreted as a reduction in direct exposure to the company's stock, although this was pre-planned.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common occurrences in the biotechnology and pharmaceutical sectors as executives manage their equity compensation and personal financial planning. These pre-scheduled sales are generally viewed as less indicative of management's immediate sentiment about the company's future prospects compared to unscheduled open market sales or purchases.
Stakeholder Impact
- Shareholders: The sale of shares by an executive could be perceived as a slight negative, but the 10b5-1 plan context suggests it's for personal financial planning rather than a lack of confidence in the company.
- Employees: No direct impact.
Key Dates
| Date | Description |
|---|---|
| 2020-01-02 | Earliest exercisable date for 385 non-qualified stock options with an exercise price of $52.87. |
| 2023-01-03 | Earliest exercisable date for 6,951 non-qualified stock options with an exercise price of $32.60. |
| 2024-01-03 | Earliest exercisable date for 3,510 non-qualified stock options with an exercise price of $37.58. |
| 2025-09-29 | Earliest exercisable date for 3,760 non-qualified stock options with an exercise price of $40.85. |
| 2025-11-24 | Date the Rule 10b5-1 Trading Plan was adopted by the reporting person. |
| 2026-01-02 | Earliest exercisable date for 5,500 non-qualified stock options with an exercise price of $34.69. |
| 2026-03-03 | Date of reported transactions (stock option exercises and sales). |
| 2026-03-05 | Date the Form 4 was signed. |
| 2032-01-02 | Expiration date for 6,951 non-qualified stock options with an exercise price of $32.60. |
| 2033-01-02 | Expiration date for 3,510 non-qualified stock options with an exercise price of $37.58. |
| 2034-01-01 | Expiration date for 385 non-qualified stock options with an exercise price of $52.87. |
| 2034-09-28 | Expiration date for 3,760 non-qualified stock options with an exercise price of $40.85. |
| 2035-01-01 | Expiration date for 5,500 non-qualified stock options with an exercise price of $34.69. |
Recommendation
holdThe transactions reported are routine insider sales executed under a pre-arranged 10b5-1 plan, which are common for executive compensation management. They do not provide new fundamental insights into Ionis Pharmaceuticals' operational performance or strategic direction that would warrant a change in investment recommendation. Investors should maintain their current position and focus on the company's core business developments and financial reports.
Keywords
Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Shannon L. Devers, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.